UNII XF417D3PSL

ANHYDROUS CITRIC ACID

Unique Ingredient Identifier XF417D3PSL is listed as a ingredient substance

• RN: 77-92-9
• EC: 201-069-1
• NCIT: C80088
• RXCUI: 221946
• PUBCHEM: 311
• MF: C6H8O7
• INCHI KEY: KRKNYBCHXYNGOX-UHFFFAOYSA-N
• SMILES: OC(=O)CC(O)(CC(O)=O)C(O)=O

Dosage Forms

UNII XF417D3PSL ANHYDROUS CITRIC ACID is commonly included in medications in the following forms.

Route	Dosage Form	Potency
BUCCAL	FILM	1.04 MG
IM - IV	INJECTION	0.33 %
INHALATION	SUSPENSION	0.56 mg/2mL
INTRACARDIAC	INJECTION	12.5 mg/5mL
INTRAMUSCULAR	INJECTION	12.5 mg/5mL
INTRAMUSCULAR	INJECTION	0.2 %W/V
INTRAMUSCULAR	INJECTION, SOLUTION	0.25 %
INTRAVENOUS	INJECTABLE	0.2 %
INTRAVENOUS	INJECTION	10 MG/1ML
INTRAVENOUS	INJECTION	7.7 %W/V
INTRAVENOUS	INJECTION, SOLUTION	0.4 %W/V
INTRAVENOUS	LIQUID	2 MG/1ML
INTRAVENOUS	LIQUID	0.2 %
INTRAVENOUS	POWDER, FOR INJECTION SOLUTION, LYOPHILIZED	42.19 %
INTRAVENOUS	SOLUTION, INJECTION	1 %
INTRAVENOUS	SOLUTION, INJECTION	0.14 ADJ PH
INTRAVENOUS INFUSION	INJECTION	4 MG/1ML
INTRAVENOUS INFUSION	SOLUTION, INJECTION	0.53 %
INTRAVENOUS INFUSION	SOLUTION, INJECTION	0.025 mg/mL
IV(INFUSION)	INJECTABLE	7.7 %W/V
IV(INFUSION)	SOLUTION, CONCENTRATE	0.6 %
IV(INFUSION)	SOLUTION, INJECTION	1 %
NASAL	SOLUTION, SPRAY	0.044 %
NASAL	SPRAY	0.058 %
NASAL	SPRAY, METERED	0.045 %
OPHTHALMIC	SOLUTION	0.93 MG/1ML
ORAL	CAPSULE, SOFT GELATIN	1.64 MG
ORAL	CAPSULE, SOFT GELATIN LIQUID-FILLED	30 MG
ORAL	GRANULE, FOR ORAL SUSPENSION	4.9 MG
ORAL	LIQUID	2 MG/1ML
ORAL	LIQUID	2 mg/10mL
ORAL	LIQUID,EXTENDED RELEASE	5.18 MG/ML
ORAL	POWDER, FOR ORAL SOLUTION	210 MG
ORAL	POWDER, FOR ORAL SUSPENSION	100 mg
ORAL	POWDER, FOR ORAL SUSPENSION	60 MG/PKT
ORAL	POWDER, FOR SOLUTION	7.99 MG
ORAL	POWDER, FOR SUSPENSION	10 MG/140ML
ORAL	SOLUTION	33.18 MG/5ML
ORAL	SOLUTION	15 mg/5 mL
ORAL	SOLUTION	0.675 mg/15 mL
ORAL	SOLUTION	ADJ PH
ORAL	SOLUTION, ELIXIR	5 MG/5ML
ORAL	SOLUTION, LIQUID	0.8 MG/1ML
ORAL	SUSPENSION	75 MG/5ML
ORAL	SUSPENSION	5.1 MG/5 ML
ORAL	SUSPENSION	4.9 mg/1mL
ORAL	SUSPENSION	2.25 mg/1.25mL
ORAL	SUSPENSION, DROPS	2.5 MG/1ML
ORAL	SUSPENSION, EXTENDED RELEASE	2.25 MG/1ML
ORAL	SYRUP	22.32 MG/5ML
ORAL	SYRUP	0.7 MG/ML
ORAL	TABLET	20.4 MG
ORAL	TABLET	ADJ PH
ORAL	TABLET, CHEWABLE	8 MG
ORAL	TABLET, EFFERVESCENT, FOR SOLUTION	839.63 MG
ORAL	TABLET, EXTENDED RELEASE	78 MG
ORAL	TABLET, ORALLY DISINTEGRATING	30 MG
ORAL	TABLET, ORALLY DISINTEGRATING	ADJ PH
ORAL	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	8 mg
ORAL	TABLET, UNCOATED, LOZENGE	9.8 MG
RECTAL	SUSPENSION	0.11 %
RESPIRATORY (INHALATION)	SOLUTION, SPRAY	0.0003 %
RESPIRATORY (INHALATION)	SUSPENSION, FOR INHALATION	0.027 %
SUBCUTANEOUS	INJECTION	12.5 mg/5mL
SUBCUTANEOUS	INJECTION	0.2 %
SUBCUTANEOUS	INJECTION, SOLUTION	0.25 %
SUBLINGUAL	FILM	5.56 mg
SUBLINGUAL	TABLET	10 MG
SUBLINGUAL	TABLET (IMMED./COMP. RELEASE), UNCOATED, BUCCAL	6 MG
SUBLINGUAL	TABLET, ORALLY DISINTEGRATING	ADJ PH
TOPICAL	AEROSOL	0.01 %W/W
TOPICAL	AEROSOL, FOAM	ADJPH
TOPICAL	AEROSOL, FOAM	ADJ PH
TOPICAL	CLOTH	0.15 %W/W
TOPICAL	CREAM	0.05 %W/W
TOPICAL	CREAM	0.01 %W/W
TOPICAL	CREAM, EMULSION, SUSTAINED RELEASE	0.18 %W/W
TOPICAL	EMULSION, AEROSOL FOAM	0.08 %W/W
TOPICAL	EMULSION, CREAM	0.05 %W/W
TOPICAL	GEL	0.05 %W/W
TOPICAL	LOTION	0.42 %W/W
TOPICAL	OIL	0.03 %W/W
TOPICAL	OPHTHALMIC SUSPENSION DOSAGE FORM	0.05 %W/V
TOPICAL	SOLUTION	0.93 MG/1ML
TOPICAL	SOLUTION	0.2 %W/W
TRANSDERMAL	PATCH, ELECTRICALLY CONTROLLED	23 MG
TRANSMUCOSAL	TABLET, UNCOATED, LOZENGE	11 MG